Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?

Addiction

Volumn 107, Issue 2, 2012, Pages 241-247

  Ambermoon, Polly ^a   Carter, Adrian ^a,b   Hall, Wayne ^a,c   Dissanayaka, Nadeeka ^a,d   O'Sullivan, John ^c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Addiction; Dopamine dysregulation syndrome; Dopamine replacement therapy; Impulse control disorders; Parkinson's disease; Psychostimulants

Indexed keywords

ANTIPARKINSON AGENT; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADDICTION; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; HUMAN; IMPULSE CONTROL DISORDER; PARKINSON DISEASE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; SYNDROME;

ANTIPARKINSON AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; PARKINSON DISEASE; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; SYNDROME;

EID: 84855915256     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03511.x     Document Type: Article

References (67)

1. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: S3-7.
2. O'Sullivan S. S., Evans A. H., Lees A. J. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23: 157-70.
3. Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 1987; 17: 899-904.
4. Witjas T., Kaphan E., Azulay J. P., Blin O., Ceccaldi M., Pouget J. etal. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-13.
5. Merims D., Giladi N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord 2008; 14: 273-80.
6. Giovannoni G., O'Sullivan J. D., Turner K., Manson A. J., Lees A. J. L. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-8.
7. Spigset O., von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997; 17: 1027-30.
8. Merims D., Galili-Mosberg R., Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Mov Disord 2000; 15: 1014-6.
9. Rabinak C. A., Nirenberg M. J. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58-63.
10. Evans A. H., Lawrence A. D., Cresswell S. A., Katzenschlager R., Lees A. J. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010; 25: 867-76.
11. Priebe S. Levodopa dependence: a case report. Pharmacopsychiatry 1984; 17: 109-10.
12. Nausieda P. A. Sinemet 'abusers'. Clin Neuropharmacol 1985; 8: 318-27.
13. Lawrence A. D., Evans A. H., Lees A. J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
14. Bearn J., Evans A., Kelleher M., Turner K., Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 2004; 76: 305-10.
15. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM-IV-TR). Washington, DC: APA; 2000.
16. Tack E, De Cuypere G, Jannes C, Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 1988; 78: 356-60.
17. Ross R. G., Ward N. G. Bromocriptine abuse. Biol Psychiatry 1992; 31: 404-6.
18. Soyka M., Huppert D. L-dopa abuse in a patient with former alcoholism. Br J Addict 1992; 87: 117-8.
19. Weinman E., Ruskin P. E. Levodopa dependence and hypersexuality in an older Parkinson's Disease patient. Am J Geriatr Psychiatry 1995; 3: 81-3.
20. Courty E., Durif F., Zenut M., Courty P., Lavarenne J. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease. Clin Neuropharmacol 1997; 20: 140-7.
21. Gschwandtner U., Aston J., Renaud S., Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001; 24: 170-2.
22. Serrano-Duenas M. Chronic dopamimetic drug addiction and pathologic gamlbing in patient's with Parkinson's disease-presentation of four cases. Ger J Psychiatry 2002; 5: 62-6.
23. Houeto J. L., Mesnage V., Mallet L., Pillon B., Gargiulo M., du Moncel S. T. etal. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-7.
24. Steiner I., Wirguin I. Levodopa addiction in non-parkinsonian patients. Neurology 2003; 61: 1451.
25. Dodd M. L., Klos K. J., Bower J. H., Geda Y. E., Josephs K. A., Ahlskog J. E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1377-81.
26. Lily O., Al-Din A. Case study: cerebrovascular parkinsonism with levodopa addiction. J Neurol Neurosurg Psychiatry 2004; 75: 1365-6.
27. Borek L. L., Friedman J. H. Levodopa addiction in idiopathic Parkinson disease. Neurology 2005; 65: 1508.
28. Witjas T., Baunez C., Henry J. M., Delfini M., Regis J., Cherif A. A. etal. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005; 20: 1052-5.
29. Pezzella F. R., Colosimo C., Vanacore N., Di Rezze S., Chianese M., Fabbrini G. etal. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20: 77-81.
30. Tellez C., Bustamante M. L., Toro P., Venegas P. Addiction to apomorphine: a clinical case-centred discussion. Addiction 2006; 101: 1662-5.
31. Solla P., Floris G., Tacconi P., Cannas A. Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation. Int J Neuropsychopharmacol 2006; 9: 767-8.
32. Kummer A., Maia D. P., Salgado J. V., Cardoso F. E. C., Teixeira A. L. Dopamine dysregulation syndrome in Parkinson's disease-case report. Arq Neuropsiquiatr 2006; 64: 1019-22.
33. Kessel B. L. A case of hedonistic homeostatic dysregulation. Age Ageing 2006; 35: 540-1.
34. Nirenberg M. J., Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21: 524-9.
35. Knobel D., Aybek S., Pollo C., Vingerhoets F. J., Berney A. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 2008; 21: 187-9.
36. Harper A., Bayliss M., Saha R., Scutt A., Nisbet A. Late onset dopa-responsive dystonia with tremor, gait freezing and behavioural disturbance and a normal dopamine transporter scan. Age Ageing 2008; 37: 719-20.
37. Avanzi M., Baratti M., Cabrini S., Uber E., Brighetti G., Bonfa F. The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome? Parkinsonism Relat Disord 2008; 14: 257-8.
38. Sammler E. M., Swingler R. J., Stuart A., Muqit M. Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations. Mov Disord 2009; 24: 2442-3.
39. Salas R. E., Allen R. P., Earley C. J., Gamaldo C. E. Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. Mov Disord 2009; 24: 627-8.
40. Leu-Semenescu S., Karroum E., Brion A., Konofal E., Arnulf I. Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Med 2009; 10: 494-6.
41. Schwingenschuh P., Katschnig P., Saurugg R., Ott E., Bhatia K. P. Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? Mov Disord 2010; 25: 493-6.
42. Kenangil G., Ozekmekci S., Sohtaoglu M., Erginoz E. Compulsive behaviors in patients with Parkinson's disease. Neurologist 2010; 16: 192-5.
43. O'Sullivan S. S., Djamshidian A., Ahmed Z., Evans A. H., Lawrence A. D., Holton J. L. etal. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Mov Disord 2010; 25: 638-42.
44. Lim S. Y., O'Sullivan S. S., Kotschet K., Gallagher D. A., Lacey C., Lawrence A. D. etal. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148-52.
45. Happe S., Sommer M., Meller J., Trenkwalder C., Paulus W. Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder. Mov Disord 2005; 20: 105-8.
46. Evans A. H., Lawrence A. D., Potts J., Appel S., Lees A. J. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65: 1570-4.
47. Nyholm D., Karlsson E., Lundberg M., Askmark H. Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol 2010; 17: 260-6.
48. Goetz C. G., Tilley B. C., Shaftman S. R., Stebbins G. T., Fahn S., Martinez-Martin P. etal. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-70.
49. Gallagher D. A., O'Sullivan S. S., Evans A. H., Lees A. J., Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007; 22: 1757-63.
50. Pezzella F. R., Di Rezze S., Chianese M., Fabbrini G., Vanacore N., Colosimo C. etal. Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire. Neurol Sci 2003; 24: 205-6.
51. Cabrini S., Baratti M., Bonfa F., Cabri G., Uber E., Avanzi M. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci 2009; 30: 307-13.
52. Weintraub D., Hoops S., Shea J. A., Lyons K. E., Pahwa R., Driver-Dunckley E. D. etal. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009; 24: 1461-7.
53. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-80.
54. Robbins T. W., Everitt B. J. Drug addiction: bad habits add up. Nature 1999; 398: 567-70.
55. Swainson R., Rogers R. D., Sahakian B. J., Summers B. A., Polkey C. E., Robbins T. W. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000; 38: 596-612.
56. Evans A. H., Pavese N., Lawrence A. D., Tai Y. F., Appel S., Doder M. etal. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-8.
57. Berke J. D., Hyman S. E. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000; 25: 515-32.
58. Redgrave P., Rodriguez M., Smith Y., Rodriguez-Oroz M. C., Lehericy S., Bergman H. etal. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci 2010; 11: 760-72.
59. Wiecki T. V., Frank M. J. Neurocomputational models of motor and cognitive deficits in Parkinson's disease. Prog Brain Res 2010; 183: 275-97.
60. Cools R., Lewis S. J., Clark L., Barker R. A., Robbins T. W. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007; 32: 180-9.
61. van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J. M., Lang A. E., Strafella A. P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in parkinson's disease? Neuropsychopharmacology 2009; 34: 2758-66.
62. Potenza M. N., Steinberg M. A., Skudlarski P., Fulbright R. K., Lacadie C. M., Wilber M. K. etal. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60: 828-36.
63. Brand M., Labudda K., Kalbe E., Hilker R., Emmans D., Fuchs G. etal. Decision-making impairments in patients with Parkinson's disease. Behav Neurol 2004; 15: 77-85.
64. Rossi M., Gerschcovich E. R., De Achaval D., Perez-Lloret S., Cerquetti D., Cammarota A. etal. Decision-making in Parkinson's disease patients with and without pathological gambling. Eur J Neurol 2010; 17: 97-102.
65. Blum K., Noble E. P. Reward deficiency syndrome (RDS): a biogenic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Mol Psychiatry 2001; 6: S2-S.
66. Dagher A., Robbins T. W. Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61: 502-10.
67. American Psychiatric Association. DSM-V Development, 2010 2010. Available at: (accessed 13 November: archived by Webcite at on 16 March, 2011).